menu
    • menu
    [{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Deuterated Psilocybin Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Artelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"4","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"}]

    Find Clinical Drug Pipeline Developments & Deals by Worldwide Clinical Trials

    Menu

    Worldwide Clinical Trials

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ART26.12

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Artelo Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Artelo Selects Worldwide Clinical Trials to Support Study of ART26.12

                            Details : Under the partnership, Worldwide Clinical Trials will support the Phase 1 trial of ART26.12, a FABP5 inhibitor being developed for chemotherapy-induced peripheral neuropathy (CIPN).

                            Brand Name : ART26.12

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : ART26.12

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Artelo Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deuterated Psilocybin Analog

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cybin

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cybin Partners with Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depres...

                            Details : Under the partnership, Worldwide Clinical Trials will support clinical developments of CYB003, an investigational proprietary deuterated analog of psilocybin, currently in Phase 2 trial for the treatment of major depressive disorder.

                            Brand Name : CYB003

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 26, 2023

                            Lead Product(s) : Deuterated Psilocybin Analog

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cybin

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : AC Immune

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, to Treat...

                            Details : ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.

                            Brand Name : ACI-24.060

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 27, 2023

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : AC Immune

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Worldwide Clinical Trials

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Neurotrope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of ...

                            Details : Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 30, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Neurotrope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth